Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
2018
Background
We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
13
Citations
NaN
KQI